PMID- 30497233
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20210109
IS  - 1827-1936 (Electronic)
IS  - 1824-4785 (Linking)
VI  - 62
IP  - 4
DP  - 2018 Dec
TI  - Role of PET imaging in adaptive radiotherapy for lymphoma.
PG  - 411-419
LID - 10.23736/S1824-4785.18.03089-3 [doi]
AB  - Positron emission tomography/Computed tomography (PET/CT) is an essential part of 
      modern radiotherapy for patients with lymphoma. PET/CT can be used to adapt 
      treatment algorithms in Hodgkin lymphoma, reserving consolidation radiotherapy 
      for patients with residual fluoro-D-glucose (FDG) avidity after treatment with 
      intensive chemotherapy such as escalated BEACOPP and limiting the need for 
      radiotherapy for some patients with complete metabolic response on PET if 
      radiotherapy may be associated with increased toxicity. More importantly, PET/CT 
      is now mandatory to define sites of initial disease for radiotherapy planning 
      where smaller volumes are to be used rather than historical extended field 
      treatments, such as mantle radiotherapy or even involved field radiotherapy. 
      Involved node radiotherapy (INRT) treats only the initially involved nodes and is 
      possible when the pretreatment PET/CT scan has been performed in the radiotherapy 
      treatment position. Involved site radiotherapy (ISRT) builds in a margin for 
      uncertainty when a pretreatment PET/CT is available, but has not been performed 
      in the radiotherapy treatment position. Studies suggest that PET/CT changes 
      radiotherapy volumes in approximately one third of patients by mapping the extent 
      of initial disease better than using CT alone. PET/CT has also been used to 
      adjust radiotherapy dose for patients who may be at increased risk of 
      radioresistance, by virtue of residual FDG avidity post chemotherapy or patients 
      with relapsed disease. This article will discuss the role of PET in selecting 
      patients for radiotherapy, its influence on the choice of target volume and 
      radiotherapy dose and the practicalities of how PET/CT scanning is incorporated 
      into the radiotherapy planning process.
FAU - Urwin, Robert
AU  - Urwin R
AD  - Guy's Cancer Centre, Guy's & St Thomas' NHS Trust, London, UK - 
      robert.urwin@gstt.nhs.uk.
FAU - Barrington, Sally F
AU  - Barrington SF
AD  - King's College London and Guy's and St Thomas' PET Centre, School of Biomedical 
      Engineering and Imaging Sciences, King's College London, King's Health Partners, 
      London, UK.
FAU - Mikhaeel, N George
AU  - Mikhaeel NG
AD  - Guy's Cancer Centre, Guy's & St Thomas' NHS Trust, London, UK.
AD  - Cancer Division, Faculty of Life Sciences and Medicine, King's College 
      University, London, UK.
LA  - eng
GR  - RP-2016-07-001/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Q J Nucl Med Mol Imaging
JT  - The quarterly journal of nuclear medicine and molecular imaging : official 
      publication of the Italian Association of Nuclear Medicine (AIMN) [and] the 
      International Association of Radiopharmacology (IAR), [and] Section of the 
      Society of...
JID - 101213861
SB  - IM
MH  - Humans
MH  - Image Processing, Computer-Assisted
MH  - Lymphoma/*diagnostic imaging/pathology/*radiotherapy
MH  - Positron-Emission Tomography/*methods
MH  - Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted
MH  - Radiotherapy, Image-Guided/*methods
EDAT- 2018/12/01 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/12/01 06:00
PHST- 2018/12/01 06:00 [entrez]
PHST- 2018/12/01 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - S1824-4785.18.03089-3 [pii]
AID - 10.23736/S1824-4785.18.03089-3 [doi]
PST - ppublish
SO  - Q J Nucl Med Mol Imaging. 2018 Dec;62(4):411-419. doi: 
      10.23736/S1824-4785.18.03089-3.